R. Phillip Dellinger, MD, MSc, MCCM, Cooper University Health Care, USABut it’s not the first time Professor Dellinger is Professor of Medicine and Emeritus Research at Cooper Medical School of Rowan University (CMSRU) and Senior Critical Care at Cooper University Hospital. beyond president of the Society of Critical Care Medicine (SCCM) and was the 15th winner of the SCCM Lifetime Achievement Award in 2015. He was the leader of the 2004, 2008 and 2012 campaign guidelines to survive sepsis, severe sepsis management and septic shock and leader of the 2016 guidelines.
GaliaRahav, MD, PhD Sheba Medical Center, Israel Professor Rahav is Head of the Laboratory and Infectious Diseases Unit at Sheba Medical Center, and a full professor of internal and infectious diseases at Tel Aviv University’s Sackler School of Medicine. RE. in Medicine from the Faculty of Medicine of the Hebrew University of Hadassah in Jerusalem and holds a certificate of specialization in internalArray infectious diseases and clinical microbiology.
Christian Putensen, MD, PhD, University Hospital Bonn, Germany Professor Putensen is Professor of Intensive Care Medicine and Head of the Division of Intensive Care Medicine, Department of Anesthesiology and Intensive Care Medicine, at the University Hospital in Bonn. former member of the executive committee and former chairman of the breathing segment of the European Society of Intensive Care Medicine. He is currently chairman of the Scientific Subcommittee on Intensive Care Medicine of the European Society of Anesthesiology and Intensive Care Medicine. Professor Putensen’s studies focus on physiopathology and the remedy for acute respiratory misery syndrome and sepsis.
Tom van der Poll, MD, PhD, University of Amsterdam Medical Centers, Netherlands Professor van der Poll is professor of medicine and president of the Department of Medicine at the University of Amsterdam (Academic Medical Center – University of Amsterdam – and Free University Medical Center) in the Netherlands. He holds a degree in internal medicine and infectious diseases. Professor van der Poll has made basic contributions to the physiopathology of sepsis.
Professor Dellinger, chairman of the CoVID-19 Pluristem Steering Committee, commented: “In the absence of remedies approved for SDRA due to COVID-19 to be obtained today, I am honored to chair the multi-system guidance committee. colleagues to provide recommendations on the progression of COVID-19 treatment of Pluristem, which has the potential to help severe patients in need around the world. “
“We have assembled this guidance committee, made up of prestigious leaders in their fields around the world, so that consultants and assistance drive PLX-PAD’s path of clinical progression at this critical time. We greatly appreciate the knowledge, skill, and each of these key opinion leaders as we join forces to provide effective mobile treatment for the most serious CASES of COVID-19,” said Pluristem CEO and President Yaky Yanay.
Safe Harbor Statement This press release comprises explicit or implied forward-looking statements in the Private Securities Litigation Reform Act of 1995 and other US federal securities laws. For example, Pluristem uses forward-looking statements when discussing the possibility of COVID-19 remedy from Pluristem to help critically ill patients in need worldwide and that Pluristem and its COVID-19 guidance committee will advise and help drive the clinical progression of PLX-PAD. and walk. These forward-looking statements and their implications are based solely on the existing expectations of Pluristem’s control and are subject to a number of points and uncertainties that may also cause the actual effects to differ materially from those described in the forward-looking statements. . The following, among others, may also cause actual effects to differ materially from those described in the forward-looking statements: adjustments in generation requirements and market place; Pluristem would possibly encounter delays or obstacles in the launch and / or good fortune of its clinical trials; Pluristem products might not be approved through regulatory agencies, the Pluristem generation might not be validated as it progresses, and its strategies might not be accepted by the clinical community; Pluristem could not possibly retain or attract key workers whose wisdom is essential for the progression of its products; unforeseen clinical difficulties would possibly expand with the Pluristem process; Pluristem products may end up being more expensive than you expect; laboratory effects may not translate into equally intelligent effects in real clinical settings; the effects of preclinical studies may not correlate with the effects of human clinical trials; Pluristem patents might not be enough; Pluristem products could potentially harm recipients; adjustments in the law would possibly have a negative effect on Pluristem; the inability to expand and introduce new technologies, products, and programs in a timely manner; loss of market place percentage and value stress as a result of competition, which may also cause Pluristem’s actual effects or functionality to differ materially from those considered in those forward-looking statements. Unless otherwise provided by law, Pluristem assumes no legal responsibility to publicly publish any revisions to such forward-looking statements to reflect events or events close to the date hereof or to reflect the occurrence of unforeseen events. For a more detailed description of the dangers and uncertainties affecting Pluristem, reference is made to Pluristem’s reports that are filed from time to time with the Securities and Exchange Commission.
Contact:
Dana RubinDirector of Investor Relations 972-74-7107194danar@pluristem. com